Elite Pharmaceuticals, Inc. to Present at the Oppenheimer ''Positioning Investors for the Next Wave in Pain Management’’ Conference in New York City on March 6, 2007

NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals Inc. (“Elite” or the “Company”) (AMEX: ELI), will present at the Oppenheimer “Positioning Investors for the Next Wave in Pain Management” Conference on Tuesday, March 6, 2007. Bernard Berk, Elite’s Chairman and Chief Executive Officer, will discuss the Company’s two lead opioid products: ELI-216, the Company’s abuse-deterrent oxycodone hydrochloride product using ART ™ , and ELI-154, its once-daily oxycodone hydrochloride.